toxylact: a0ag03 dantron including combinations

The first professional lActological database in the word

Dantron and its combinations (ATC A06AG03) are stimulant laxatives used mainly as rectal preparations for the short‑term management of constipation, but they pose relevant toxicological concerns and are generally avoided during breastfeeding because of carcinogenic potential and limited lactation data.hpra+2

Pharmacological class and clinical use

ATC class A06AG03 comprises dantron‑containing enema and rectal products, either as single‑ingredient or in fixed combinations with other laxatives (for example docusate sodium), used to restore bowel evacuation in patients with chronic constipation or in palliative care settings.wikidoc+1
Dantron is an anthraquinone‑derivative stimulant laxative that enhances colonic peristalsis by stimulating sensory nerve endings in the colonic mucosa, thereby facilitating defecation.wikidoc+1
Clinical use is usually restricted to short courses and, in some jurisdictions (e.g. UK and Ireland), to patients with terminal cancer because of concerns regarding carcinogenicity.hpra+1

Toxicology profile

Dantron (1,8‑dihydroxyanthraquinone) has shown intestinal tumours in rats and mice and hepatocarcinogenic effects in experimental animals after oral administration, which underlies regulatory restrictions on its use.hpra+1
Reported adverse effects in humans include allergic reactions, headache, hypotension, cardiac arrhythmias and red discoloration of urine, reflecting its systemic absorption and local mucosal irritant action.wikidoc+1
Given its genotoxic and carcinogenic signal in animal studies and lack of long‑term human safety data, dantron is considered potentially hazardous for chronic use and is generally reserved for situations where safer laxatives are ineffective or inappropriate.medsafe+2

Lactation and breastfeeding considerations

There are no robust pharmacokinetic or clinical studies quantifying dantron transfer into breast milk or documenting outcomes in breastfed infants, and major lactation resources focus instead on safer alternative laxatives such as docusate and polyethylene glycol.ncbi.nlm.nih+2
General principles in lactation toxicology advise that medicines with carcinogenic potential or poorly characterized infant exposure should be avoided during breastfeeding when safer options exist, even if maternal doses are low and exposure via milk is likely below 10% of the maternal dose.who+1
For nursing mothers with constipation, guidelines and expert resources recommend using non‑anthraquinone laxatives (e.g. osmotic agents such as polyethylene glycol, or stool softeners such as docusate) that have better documented safety rather than dantron‑containing preparations.mayoclinic+2

Risk assessment and clinical recommendations

From a toxicological perspective, the combination of experimental carcinogenicity, stimulant action on colonic mucosa and absence of milk‑transfer data supports classifying dantron and its combinations as drugs that should generally be avoided in breastfeeding women unless there is a compelling indication and safer alternatives have failed.hpra+2
If dantron must be used in a lactating patient (for example, in palliative oncology with refractory constipation), the course should be as short as possible, at the lowest effective dose, with close monitoring of the infant for gastrointestinal symptoms and with shared decision‑making that weighs maternal benefits against potential long‑term cancer risk to the child.who+1
Healthcare professionals managing constipation in breastfeeding women are advised to consult dedicated lactation drug databases (such as LactMed) and national evidence‑based breastfeeding medication guidelines, and to preferentially select laxatives with established safety profiles.ncbi.nlm.nih+2

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.